![]() All in all, it is a good addition and it has good data behind it. It is always good to have some options available to us, in case patients need it. It has a slightly different effect profile than other BTK inhibitors. It's the second-generation BTK inhibitor, we previously had ibrutinib and acalabrutinib. Zanubrutinib is the third BTK inhibitor that was approved recently for CLL and SLL in the frontline setting, and of course, the relapsed setting was there already. TARGETED ONCOLOGY: Can you discuss the approval of zanubrutinib for CLL and SLL? What is the potential impact of this approval? In the interview, Khan reviewed the recent FDA approvals is the CLL space and discussed other FDA decisions that have recently altered the landscape for the better. Then, perhaps we can put them on another drug for some time to slightly reduce the toxicity,” Khan told Targeted OncologyTM, in an interview. Instead, we might expose patients for 6 to 12 months. ![]() ![]() We won’t expose the patients to the long-term toxicity of these drugs. I think, in the future, if some of these drugs come out, probably a more time-limited treatment would be better. “We use all these novel agents in the same fashion where we continue them until progression or toxicity. ![]() This tactic may improve outcomes overall. Khan, a hematologist in the Division of Hematology and Cellular Therapy at West Penn Hospital of Allegheny Health Network, explained that it would be the best interest of investigators to limit the amount of time a patient is on certain drugs, in the future. Regarding prospective agents, there have been continuous reports of positive efficacy in clinical trials of patients with CLL/SLL, but safety has been of concern for some therapies. Khan, MD, the current drug pipeline is also abundant with promising prospects. An array of Bruton’s tyrosine kinase (BTK) inhibitors are available for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |